Sign up online today & collaborate
or click here to find out more
06 October 2015: Oxford, UK & Philadelphia, USA – Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced plans to expand its research and development operation into a major new purpose-built facility at Milton Park, Oxfordshire.
Construction of Adaptimmune’s 67,000 square foot ‘Enterprise Zone’ building is already under way following a traditional groundbreaking ceremony. The flagship facility will provide laboratory space with associated offices, meeting rooms and a café area to accommodate a team of around 200 highly-skilled research and development specialists.
The new building is designed to support the Company’s continuing growth of its research and development operation, complementing the simultaneous expansion of its clinical and manufacturing operation in Philadelphia, and is scheduled for delivery in late 2016.
Adaptimmune has signed a 25-year agreement with break options to lease the building from developer MEPC, which owns Milton Park, one of Europe’s largest business parks and home to over 7,500 employees and 250 organizations.